Hypoglycemia is a frequent occurrence in patients with diabetes who are treated with insulin and insulin secretagogues. Hypoglycemia is the limiting factor that prevents patients from achieving the glycemic control known to reduce the microvascular complications of diabetes. Recurrent episodes of hypoglycemia can lead to impaired awareness of hypoglycemia where the first symptom of a low blood sugar is unconsciousness. The fear of hypoglycemia has a significant effect on the quality of life of patients and their families. In the acute setting, hypoglycemia can kill, and clinical trials have demonstrated that a single episode of severe hypoglycemia increases the risk of subsequent mortality and cardiovascular events. Clinicians must make efforts to recognize and prevent hypoglycemia in order to prevent the adverse events associated with this event. Patient education is central to these efforts. Recent developments in glucose monitoring and drug development have provided more approaches that can be used to reduce the risk of hypoglycemia in patients with diabetes.
|Translated title of the contribution||Hypoglycemia in diabetes: The dark side of diabetes treatment. A patient-centered review|
|Original language||Chinese (Traditional)|
|Number of pages||8|
|Journal||Journal of Diabetes|
|State||Published - 2019|
Bibliographical noteFunding Information:
BJ‐R declares no conflict of interest. ERS has previously consulted for Sanofi, Lilly, and Zucara, her institution has received grant funding from Lilly for her research, and she is a member of the International Hypoglycemia Study Group that is supported by an unrestricted grant from Novo Nordisk.
© 2019 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd
- cardiovascular disease
PubMed: MeSH publication types
- Journal Article